- Developing innovative cancer immunotherapies
- Four lead products in development
- Phase II and phase I/II studies in preparation targeting multiple cancer indications
What the company does
AIM-listed Scancell Holdings PLC (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing promise – they are the ImmunoBody and Moditope platforms. The former has spawned the company’s most advanced cancer drugs, SCIB-1 and SCIB-2. It is also developing MODI-1 and MODI-2 from the Moditope platform.
In April the firm said it was to kick off the UK arm of the phase II clinical trial of its flagship skin cancer drug within weeks, after receiving approval from regulators. The study will test the safety and efficacy of SCIB1 in 25 metastatic melanoma patients who are also receiving Merck’s blockbuster checkpoint inhibitor, Keytruda.
The UK arm of the trial is scheduled to get underway before the end of June, and the Scancell team are working to secure approvals from US regulators so trials can also start across the pond. Last October, the US Food and Drug Administration (FDA) requested some more information around TriGrid – a delivery system developed by a third party – before granting SCIB1 investigational new drug status.
In May, Sancell and cancer Cancer Research UK (CRUK) announced further progress with Scancell's SCIB2 cancer immunotherapy vaccine. Pre-clinical studies have demonstrated that the administration of SCIB2 as a liposomal nanoparticle results in potent immune responses and prolonged survival.
The company expects to generate meaningful clinical data in the next two years from all four of its drug candidates (see below).
In recent updates investors have been told CRUK is planning a clinical trial to investigate the safety and efficacy of the SCIB2-nanoparticle complex in patients with solid tumours.
And a planned phase I/II clinical study is of MODI-1 is expected to begin in the second half.